Matsubara N, et al. – The safety, pharmacokinetics, and efficacy of darolutamide (ODM–201), a new–generation nonsteroidal androgen receptor antagonist were evaluated in Japanese patients with metastatic castration–resistant prostate cancer (mCRPC). Without differences in safety and pharmacokinetics relative to Western patients, recommended regimen was well tolerated at the examined doses in these patients.